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Abstract: Interleukin-8 (IL-8) is a neutrophil chemokine that is encoded on the CXCL8 gene. 
Normally CXCL8 expression is repressed due to histone deacetylation, octamer-1 binding 
to the promoter and the inhibitory effect of nuclear factor-B repressing factor (NRF). 
However, in response to a suitable stimulus, the human CXCL8 gene undergoes transcription 
due to its inducible promoter that is regulated by the transcription factors nuclear factor-B 
(NF-B), activating protein (AP-1), CAAT/enhancer-binding protein  (C/EBP, also known as 
NF-IL-6), C/EBP homologous protein (CHOP) and cAMP response element binding protein 
(CREB). CXCL8 mRNA is then stabilised by the activity of p38 mitogen-activated protein 
kinase (p38 MAPK). Cystic fibrosis (CF) lung disease is characterised by a neutrophil-dominated 
airway inflammatory response. A major factor contributing to the large number of neutrophils 
is the higher than normal levels of IL-8 that are present within the CF lung. Infection and 
inflammation, together with intrinsic alterations in CF airway cells are responsible for the 
abnormally high intrapulmonary levels of IL-8. Strategies to inhibit aberrantly high CXCL8 
expression hold therapeutic potential for CF lung disease. 
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1. Introduction 
Inflammation is an important consequence of tissue injury that can result from several causes such as 
infection, trauma, neoplasm, and autoimmune disease. This mechanism is highly regulated by small 
molecules called chemokines, which control trafficking of various types of leukocytes via interaction with 
transmembrane receptors. One important chemokine that plays a vital role in most inflammatory pathways 
is interleukin (IL)-8. 
Based on its functions, in the past, IL-8 has been alternatively named as T-cell chemotactic factor, 
neutrophil-activity peptide 1, Beta-thromboglobulin-like protein, and tumour necrosis factor-induced 
gene, amongst others. However, the name and symbol chemokine (C-X-C motif) ligand 8 and CXCL8, 
respectively, were adopted and have been officially endorsed by the Chemokine Nomenclature Subcommittee 
of the International Union of Immunological Societies [1]; nonetheless the name interleukin-8 is still 
widely used when referring to the protein. 
In humans, IL-8 is one of fifteen members of the CXC chemokine family that are mostly encoded on 
chromosome 4q, spanning a region of approximately 2.5 Mb [2]. The IL-8 gene (CXCL8) has been 
mapped to 4q12-q21 by using somatic cell hybridization and in situ hybridization. CXCL8 is 3211 bases 
in length and is encoded on 4 exons. Monocytes/macrophages, epithelial cells, smooth muscle cells and 
endothelial cells can all produce IL-8. It exists in two isoforms; a 72 amino acid form derived from 
endothelial cells and the more abundant 77 residue form secreted by monocytes and other cells [3,4]. 
The main receptors that interact with IL-8 are G-protein coupled seven transmembrane receptors CXCR1 
and CXCR2, where the former has greater affinity and expression [5,6]. 
Due to the significant role IL-8 has in the inflammatory process in various diseases, importantly its 
expression can be regulated through a number of mechanisms. For example A/U rich elements and 
microRNA recognition elements in the 3' untranslated region of the CXCL8 mRNA have been reported 
to contribute to its post-transcriptional regulation [7,8]. However, of relevance here is the fact that the 
CXCL8 promoter is regulated by a selection of inducible transcription factors. 
A major property of IL-8 during the inflammatory process is chemotaxis of target cells to the site of 
inflammation, in particular neutrophils. IL-8 also has chemotactic activity against T cells and basophils. 
Neutrophil adhesion to and transmigration across the endothelium are regulated by IL-8 and once neutrophils 
arrive to the site of inflammation, IL-8 further stimulates those cells to carry out phagocytosis, thus increasing 
the efficiency of tissue repair. Studies have also shown that IL-8 also has other immunomodulatory  
effects including the ability to induce matrix metalloproteinase-9 expression, release of TNF-related 
apoptosis-inducing ligand (TRAIL) and prime respiratory burst in neutrophils (reviewed in [9]). 
2. Transcriptional Regulation of CXCL8 
Inflammation recruits neutrophils to the site of injury, by a mechanism that is directed by chemokines. 
In the cystic fibrosis (CF) lung the most abundant chemokine is IL-8; it has variable characteristics, of 
which the most remarkable is its inducible expression which allows for variation of its expression levels. 
In non-pathological tissue, levels of IL-8 are not detectable, but are exponentially increased by 10- to 
100-fold in response to pro-inflammatory cytokines such as tumour necrosis factor (TNF) and IL-1, 
bacterial or viral virulence factors, and oxidative stress. The expression of IL-8 is highly coordinated by 
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many complex integrated signalling pathways [10] and is stimulus-dependent as shown, for example, by 
Kasahara et al. who demonstrated this phenomenon through nuclear run-on experiments in astrocytes [11]. 
The proximal region of the CXCL8 promoter spans approximately 200 nucleotides of the 5' flanking 
region of the CXCL8 gene, and is essential for transcriptional regulation of that gene [12]. Three of the 
major mechanisms responsible for CXCL8 regulation are: (i) repression of the CXCL8 promoter;  
(ii) transcriptional activation by inducible transcription factors; and (iii) mRNA stabilization. The 
following sections discuss each of these in more depth. 
2.1. Repression of the CXCL8 Promoter 
CXCL8 transcription is effectively repressed in unstimulated cells by a combination of three mechanisms: 
Deacetylation of histones, octamer-1 (Oct-1) binding, and active repression by NF-B repressing factor 
(NRF). Gene transcription is normally enhanced by histone acetylation which improves the activity of 
transcriptional enhanceosomes (TE). TEs provide multi-protein surfaces that make optimal contact with 
the proteins of the basal transcriptional machinery and thus facilitate maximal gene transcription; 
deacetylation has the opposite effect. Histone deacetylase-1 (HDAC-1) inhibition derepresses expression 
of CXCL8, and following the recruitment of CREB binding protein (CBP)/p300 to the promoter results 
in hyperacetylation of histones and chromatin remodelling ultimately relieving the repression [13,14]. 
Regarding Oct-1, it has been shown that replacing the Oct-1 repressor with nuclear factor-B (NF-B) 
and CAAT/enhancer-binding protein (C/EBP) as a consequence of IL-1 stimulation induces transcription 
at the CXCL8 promoter [15]. Likewise binding of NRF to a negative regulatory element (NRE) in the 
CXCL8 promoter, which incompletely overlaps with the NF-B response element, also represses CXCL8 
expression [16]. Experiments have shown that reduced cellular NRF levels, achieved by expressing  
anti-sense RNA, causes spontaneous CXCL8 gene expression. Mutations in the NRE site result in loss 
of NRF binding and an increase in basal CXCL8 transcription. Unusually, NRF has a dual role in CXCL8 
transcription: it acts as a repressor in the absence of a stimulus but actually functions as a co-activator to 
enhance IL-1-induced IL-8 protein production. 
2.2. Transcriptional Activation of CXCL8 by Inducible Transcription Factors 
Through mutation and deletion analysis, it was discovered that the CXCL8 promoter element contains 
NF-B, activating protein (AP-1), and C/EBP (also known as NF-IL-6) binding sites [10]. In addition 
the transcription factors C/EBP homologous protein (CHOP) [17] and cAMP response element binding 
protein (CREB) [18] can also bind the CXCL8 promoter (Figure 1 and Table 1). 
NF-B is a dimeric transcription factor composed of various homo- or heterodimeric combinations of 5 
subunits: RelA (also called p65), RelB, c-Rel, p50 (generated from the precursor p105/NF-B1) and p52 
(generated from p100/NF-B2). It is stored in the cytoplasm in its inactivated form by binding to its 
inhibitory proteins, IB and . During a stress stimulus, NF-B is activated by the phosphorylation of 
IB proteins by the IB kinases, IKK/ and IKK/Nemo. This results in the ubiquitination and rapid 
degradation of the inhibitory proteins by the proteosome, allowing NF-B to translocate to the nucleus 
and bind to the endogenous CXCL8 promoter by its RelA subunit [19]. NF-B is essential for activation 
of CXCL8 transcription, while AP-1 and C/EBP are required for maximal CXCL8 expression by 
synergising with NF-B [10,20]. 
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Figure 1. Architecture of the interleukin-8 promoter. Graphic representation of the CXCL8 
promoter showing the locations of the binding sites for transcription factors that induce its 
expression (adapted from reference [12]). 
AP-1 is a homodimer or heterodimer composed of c-Jun, Jun-B, Jun-D, Atf-2, c-Fos, Fra-1, and Fra-2 [21]. 
In contrast to NF-B which normally resides in the cytosol but translocates to the nucleus when IB is 
released, AP-1 is directly bound to its target sequence on DNA and its trans-activating activity is regulated 
by its abundance, phosphorylation of transactivation domains, and the binding of protein kinases [22]. 
AP-1 is activated through MAPKs. Interestingly all three MAPK pathways have been shown to contribute 
to CXCL8 gene expression: the extracellular-regulated protein kinase (ERK 1 and ERK 2), JUN-N 
terminal protein kinase (JNK), and p38 MAPK pathways [10]. 
The ERK pathway on its own is not a very potent inducer of IL-8, but has the potential to enhance 
IL-8 induction stimulated by NF-B [23]. Regarding JNK signalling, Krause et al. showed how JNK 
similar to NF-B, is essential for CXCL8 expression [24], most likely via activation of c-Jun. A study 
by Holtmann et al. suggested that NF-B and JNK work together for the induction of IL-8, as selectively 
blocking either pathway remarkably reduced IL-8 secretion [23]. p38 MAPK contributes to stabilisation 
of the CXCL8 transcript (see below). 
C/EBPs and CHOP are basic leucine zipper transcription factors; C/EBP- (also named NF-IL-6) not 
only regulates expression of interleukin-6 but also can bind to the CXCL8 promoter and co-operate with 
NF-B for transcription of CXCL8 [25]. CHOP regulates CXCL8 expression independently of NF-B 
[26]. Finally although CREB synergises with NF-B to induce expression of interleukin-6, there is no 
synergy between these transcription factors in the process of CXCL8 expression induced by TNF in 
astrocytes [27]. 
2.3. CXCL8 mRNA Stabilization 
Stabilization of the CXCL8 mRNA is mediated by p38 MAPK. Both MKK6 and MK2 are also 
involved in this process. MKK6 is a dual specificity MAPK kinase that activates p38 MAPK, and MK2 
(MAPK-activated protein kinase-2) is a downstream substrate of MKK6-p38 MAPK signalling [23,28,29]. 
Collectively this signalling pathway targets the A/U-rich 3' UTR of CXCL8 mRNA and stabilizes  
the transcript. 
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Table 1. Characteristics of transcription factors that regulate CXCL8 expression. 
Transcription 
Factors 
Transcription Factor 
Consensus Sequence 
Subunits/Isoforms Structure 
Position bp:  
Base Pair 
NF-B GGAATTTCC 
NF-B1 (p50 & p105) 
Dimeric 80/72 bp 
NF-B2 (p52 & p100) 
C-Rel 
RelA (p65) 
RelB 
NF-IL6/C/EBP AGTTGCAAAT 
3 Isoforms: Binds DNA as a dimer 
93/84 bp 
P17676-1 Forms stable heterodimers 
with CEBPA, CEBPD  
and CEBPG 
P17676-2 
P17676-3 
AP-1 TGACTCA 
c-Jun 
Homodimer/heterodimer 126/120 bp 
JunD 
JunB 
Atf-2 
c-Fos 
Fra-1 
Fra-2 
CHOP GTGTGATG 
Isoforms: 
Heterodimer 137/130 bp P35638-1 
P35638-2 
CREB TTTCGTCA 
Isoforms: 
Binds DNA as a dimer 171/164 bp 
P16220-1 
P16220-2 
P16220-3 
3. Interleukin-8 in the Cystic Fibrosis Lung 
In cystic fibrosis defective or dysfunctional CFTR (cystic fibrosis transmembrane conductance 
regulator) impairs chloride secretion from airway epithelial cells, leading to excessive reabsorption of 
sodium and water, causing a reduction of airway surface liquid volume and an impairment of mucociliary 
clearance [30]. This predisposes to bacterial colonisation of the lung and is associated with neutrophil 
infiltration and inflammation. The purpose of neutrophil infiltration into the lung is to kill bacteria and 
degrade damaged tissues. However an over exaggerated influx of neutrophils can lead to excessive release 
of neutrophil granule contents including superoxide anions and enzymes such as neutrophil elastase 
(NE), causing damage to the epithelium and injuring the airway structure. Many studies have reported 
higher than normal levels of IL-8 in the CF lung and this is in large part responsible for the high 
neutrophil burden within the CF lung [31–34] (Figure 2). 
IL-8 is a neutrophil chemokine produced principally by macrophages and epithelial cells in the CF 
lung in response to infective and inflammatory stimuli. Ideally this leads to neutrophil-mediated bacterial 
killing via CXCR1 and removal and degradation of damaged tissue [35]. Due to exaggerated number of 
neutrophils in the CF lung, there are higher than normal levels of superoxide, neutrophil proteases and 
DNA [36–39]. 
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Figure 2. Effects of Interleukin-8 in the cystic fibrosis lung. 
Pseudomonas aeruginosa is the most common CF lung pathogen. However many other microbes can 
also colonise the CF airways including Staphylococcus aureus, Haemophilus influenzae, Burkholderia 
cepacia, Aspergillus fumigatus and other fungi, as well as various anaerobic bacterial species [36]. 
People with CF are also prone to viral lung infections. Activation of toll-like receptors (TLRs) on epithelial 
or innate immune cells in the lung by microbial- and host-derived factors, can induce proinflammatory 
gene expression and in particular CXCL8 expression. A number of studies have reported the expression 
and function of TLRs in the CF lung and in in vitro models of CF. mRNA for TLRs 1-10 is expressed 
by non-CF tracheal, bronchial and alveolar type II airway epithelial cells. Likewise all TLRs have been 
detected in primary and transformed CF airway epithelial cells [40–42]. TLR5, for example, is expressed 
by airway epithelial cells and can mediate inflammatory responses to flagellin-expressing Pseudomonas 
aeruginosa, Burkholderia cepacia and B. cenocepacia [43,44]. It has been shown that CF airway 
epithelial cells respond to P. aeruginosa, IL-1 or TNF stimulation with an exaggerated NF-B activation 
thereby strongly inducing CXCL8 transcription [45–47]. This may be related to NADPH oxidase which 
is necessary for IL-8 synthesis in response to TLR activation by P. aeruginosa [48], however the 
response does not involve increased C/EBP [49]. Taken together these studies underscore the importance 
of infection and inflammation in contributing to the exaggerated expression of CXCL8 in the CF lung. 
A cycle of inflammation exists in the CF lung whereby neutrophil-derived products can drive CXCL8 
expression and IL-8 protein production in airway epithelial cells leading to further neutrophil recruitment. A 
major factor responsible for this is NE, a serine protease released from activated neutrophils. Its normal 
function is to degrade elastin however it can also affect proinflammatory gene expression, including 
CXCL8, in airway epithelial cells. The McElvaney group have reported the mechanism by which NE can 
induce IL-8 protein production from bronchial epithelial cells [50–52]. They demonstrated that NE cleaves 
meprin- on the epithelial cell surface leading to trans-activation of the epidermal growth factor receptor 
(EGFR) by release of a specific EGFR ligand, transforming growth factor-. EGFR then co-localises 
with TLR4 and an intracellular signalling cascade leading to NF-B activation and CXCL8 expression 
is implemented. This group also reported that NE can release heme from haemoglobin, possibly present 
in the CF lung due to micro bleeds, and that this in turn signals via a meprin/TLR/NF-B pathway also 
leading to CXCL8 induction [53]. NE has other deleterious effects in the CF unrelated to IL-8, including 
up regulation of mucin expression and the ability to degrade immunoglobulins, antiproteases, chemokine 
receptors and innate immunity proteins [35,54–56]. 
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Various intrinsic defects in CF cells have been reported that contribute to aberrant CXCL8 expression. 
For example, CF nasal airway epithelial cells have higher basal NF-B activity and IL-8 protein expression 
compared to non-CF cells, however this effect is not evident in nasal epithelial cells stimulated with 
inflammatory or infective stimuli [57]. In CF airway epithelial cells Bartling and Drumm reported how 
defective CFTR contributes to oxidative stress resulting in intrinsic alterations in HDACs and increased 
acetylation of the CXCL8 promoter [58]. Finally it has been shown that stabilisation of CXCL8 mRNA 
in CF airway epithelial cells occurs due to constitutive p38 and ERK1/2 MAPK signalling [59]. 
4. Strategies Targeting CXCL8 in Cystic Fibrosis 
Given the higher than normal levels of IL-8 in the CF lung and the deleterious consequences associated 
with this, the question arises as to whether IL-8 can be targeted therapeutically for CF? A number of 
groups have tested a variety of approaches including the use of anti-inflammatories, specific NF-B 
inhibitors, transcription factor decoys and more recently microRNA-modulation approaches. 
For example, in the CF lung CXCL8 is bound by gycosaminoglycans (GAGs); this does not interfere with 
its chemotactic activity and protects it from degradation by neutrophil proteases [60]. Treatment of people 
with CF with nebulized hypertonic saline can disrupt the interaction between IL-8 and GAGs rendering 
IL-8 susceptible to proteolytic degradation thereby decreasing neutrophil chemotaxis and facilitating 
resolution of inflammation [61]. More recent in vitro studies have shown that a CXCL8-based decoy, 
PA401, which displays no chemotactic activity but has GAG binding affinity can disrupt CXCL8:GAG 
complexes, rendering CXCL8 susceptible to proteolytic degradation [62]. CXCL8 normally promotes 
bacterial killing by neutrophils through CXCR1. However unopposed proteolytic activity in the CF 
airways cleaves CXCR1 on neutrophils and disables their bacterial-killing capacity. Hartl et al. demonstrated 
in vivo inhibition of proteases by inhalation of alpha1-antitrypsin leading to restored CXCR1 expression 
and improve bacterial killing in people with cystic fibrosis [35]. 
Regarding anti-inflammatory approaches, in vitro studies have tested the effects of genistein, fluvastatin 
and corilagin, amongst others [63–65]. Collectively these studies demonstrated that genistein reduces IL-8 
production in cultured CF bronchial gland cells by increasing cytosolic IB protein levels, fluvastatin 
decreased IL-8 production in whole blood in response to Pseudomonas or Aspergillus antigens, and 
corilagin binds to NF-B, thus inhibiting NF-B/DNA interactions and can decrease CXCL8 gene 
expression in CF bronchial IB3-1 cells. 
The transcription factor decoy approach is based on molecules mimicking the target sites of transcription 
factors and interfering with their activity when delivered into target cells. Intracellular delivery of 
double-stranded oligodeoxynucleotides (ODNs) designed to block NF-B binding to the CXCL8 promoter 
in IB3-1 and CuFi-1 cells could partially inhibit the P. aeruginosa-dependent CXCL8 transcription [66]. 
Similar ODNs delivered in vitro to IB3-1 cells significantly inhibited P. aeruginosa LPS-induced CXCL8 
mRNA expression [67]. Peptide nucleic acids (PNAs), in particular PNA-DNA-PNA (PDP) chimeras, are 
more stable than ODNs molecules. Finotti et al. have demonstrated that an NF-B-targeting PDP chimera 
acts as a strong inhibitor of CXCL8 gene expression [68]. 
Regarding microRNA modulation approaches to decrease CXCL8 production in the CF lung, three 
recent studies have determined how miRNAs that are aberrantly expressed in the CF airways and that 
regulate expression of CXCL8, may be targeted for therapeutic benefit [69–71]. The first reported on 
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miR-155, a miRNA that is highly expressed in CF lung, regulates SHIP1 and indirectly leads to increased 
IL-8 production. An inhibitor of miR-155 (antagomir-155) reversed this effect in vitro [69]. The other 
two studies on this topic have investigated miRNAs that are decreased in the CF lung that directly target 
CXCL8 mRNA. Fabbri et al. identified miR-93 as a miRNA that is decreased in IB3-1 and Cufi-1 cells 
infected with P. aeruginosa. Artificially increasing the levels of miR-93 (with pre-miR-93 transfection) 
could decrease IL-8 expression in these CF airway epithelial cells in vitro [70]. Lastly, Oglesby et al. [71] 
measured the expression and function of miRNAs decreased in the CF lung and in ENaC-transgenic 
mice that are predicted to target IL-8 mRNA. miR-17 was identified as a miRNA that regulates IL-8 and 
its expression was decreased in adult CF bronchial brushings, ENaC-transgenic mice and bronchial 
epithelial cells chronically stimulated with Pseudomonas-conditioned medium. Overexpression of miR-17 
inhibited IL-8 protein production in F508del-CFTR homozygous bronchial epithelial cells. Thus modulating 
the expression of miRNAs that target CXCL8 mRNA in CF bronchial epithelial is likely to represent a 
new therapeutic strategy for CF [71]. 
5. Conclusions 
Much is known about the transcriptional regulation of CXCL8 [12]. Detailed studies have identified the 
inducible regulatory factors involved and how these respond to different infective and pro-inflammatory 
stimuli. In the context of CF it is also known that intrinsic alterations due to defective CFTR can affect 
CXCL8 transcription and mRNA stabilization. Various studies have demonstrated the feasibility of 
inhibiting CXCL8 expression in CF airway epithelial cells and it is hoped that in the near future some of 
these strategies will be developed further and can be used for therapeutic benefit in individuals with CF. 
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